Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Background: Cisplatin based chemotherapy cures over 80% of metastatic testicular germ cell tumours (TGCT). In contrast, almost all other solid cancers in adults are incurable once they have spread beyond the primary site. Cell lines derived from TGCTs are hypersensitive to cisplatin reflecting the clinical response. Earlier findings suggested that a reduced repair capacity might contribute to the cisplatin hypersensitivity of testis tumour cells (TTC), but the critical DNA damage has not been defined. This study was aimed at investigating the formation and repair of intrastrand and interstrand crosslinks (ICLs) induced by cisplatin in TTC and their contribution to TTC hypersensitivity. Results: We observed that repair of intrastrand crosslinks is similar in cisplatin sensitive TTC and resistant bladder cancer cells, whereas repair of ICLs was significantly reduced in TTC. γH2AX formation, which serves as a marker of DNA breaks formed in response to ICLs, persisted in cisplatin-treated TTC and correlated with sustained phosphorylation of Chk2 and enhanced PARP-1 cleavage. Expression of the nucleotide excision repair factor ERCC1-XPF, which is implicated in the processing of ICLs, is reduced in TTC. To analyse the causal role of ERCC1-XPF for ICL repair and cisplatin sensitivity, we over-expressed ERCC1-XPF in TTC by transient transfection. Over-expression increased ICL repair and rendered TTC more resistant to cisplatin, which suggests that ERCC1-XPF is rate-limiting for repair of ICLs resulting in the observed cisplatin hypersensitivity of TTC. Conclusion: Our data indicate for the first time that the exceptional sensitivity of TTC and, therefore, very likely the curability of TGCT rests on their limited ICL repair due to low level of expression of ERCC1-XPF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Cellular and Molecular Life Sciences
(2013) · Cellular and Molecular Life Sciences · doi:10.1007/18.1420-9071 · Cited by 1,805
DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy
Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060570 · Cited by 1,727 · cited 1×
“In clinical studies high ERCC1 expression was associated with resistance to platinum containing therapy in various human cancers including colorectal cancer, ovarian cancer or NSCLC [28-31].”
BackgroundMolecular mechanisms of resistance and toxicity associated with platinating agents
Rabik, C. A., & Dolan, M. E. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.09.006 · Cited by 1,564 · cited 10×
“Unfortunately, however, none of these malignancies can be treated with a similar efficiency as TGCT [2].”
BackgroundInfluentialDNA damage-induced cell death by apoptosis
Roos, W. P., & Kaina, B. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.007 · Cited by 1,500 · cited 1×
“We found sustained activation of Chk2 following cisplatin treatment in TTC and conclude that persisting ICLs result in DSB formation that lead to a long-term DNA damage response and finally activation of the apoptotic pathway [19].”
BackgroundSelf-citationBosl, G. J., & Motzer, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370406 · Cited by 891
Lord, R. V., Brabender, J., Gandara, D. R., Alberola, V., Camps, C., Dómine, M., Cardenal, F., Sánchez, J. M., Gumerlock, P. H., Tarón, M., et al. (2002) · PubMed · Cited by 668
Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y.-P., Uetake, H., Danenberg, K. D., Groshen, S., Tsao-Wei, D. D., Danenberg, P. V., & Lenz, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.23.4298 · Cited by 610 · cited 1×
“In clinical studies high ERCC1 expression was associated with resistance to platinum containing therapy in various human cancers including colorectal cancer, ovarian cancer or NSCLC [28-31].”
BackgroundXeroderma Pigmentosum Group F Caused by a Defect in a Structure-Specific DNA Repair Endonuclease
Sijbers, A. M., de Laat, W. L., Ariza, R. R., Biggerstaff, M., Wei, Y.-F., Moggs, J. G., Carter, K. C., Shell, B. K., Evans, E., de Jong, M. C., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)80155-5 · Cited by 548 · cited 17×
“Cisplatininduced intrastrand crosslinks are removed by NER, and our findings suggest that testis tumour cells are basically NER proficient.”
BackgroundMethodInfluentialNiedernhofer, L. J., Odijk, H., Budzowska, M., van Drunen, E., Maas, A., Theil, A. F., de Wit, J., Jaspers, N. G. J., Beverloo, H. B., Hoeijmakers, J. H. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5776-5787.2004 · Cited by 492 · cited 3×
“In vitro and in vivo data implicate the NER factor ERCC1-XPF in the repair of ICLs in addition to its role in NER [ 16 ,17,22].”
BackgroundInfluentialReevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA
Eastman, A. (1986) · Biochemistry · doi:10.1021/bi00361a026 · Cited by 458 · cited 1×
“In contrast, interstrand crosslinks (ICLs) between the two DNA strands are minor lesions, accounting for less than 5% of all cisplatin lesions [5].”
BackgroundHorwich, A., Shipley, J., & Huddart, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68305-0 · Cited by 398 · cited 1×
“Background Over 80% of patients with metastatic testicular germ cell tumours (TGCT) can be cured using cisplatin-based chemotherapy [1].”
BackgroundRepair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance
McHugh, P. J., Spanswick, V. J., & Hartley, J. A. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00454-5 · Cited by 376
Cisplatin resistance: Preclinical findings and clinical implications
Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.004 · Cited by 361 · cited 1×
“In clinical studies high ERCC1 expression was associated with resistance to platinum containing therapy in various human cancers including colorectal cancer, ovarian cancer or NSCLC [28-31].”
BackgroundSelf-citationATR-Chk2 Signaling in p53 Activation and DNA Damage Response during Cisplatin-induced Apoptosis
Pabla, N., Huang, S., Mi, Q.-S., Daniel, R., & Dong, Z. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707568200 · Cited by 309 · cited 2×
“However, both Chk1 and Chk2 have been implicated in cisplatin damage signaling [14,15].”
BackgroundKöberle, B., Masters, J. R. W., Hartley, J. A., & Wood, R. D. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80118-3 · Cited by 300 · cited 3×
“These findings in living cells, however, are in contrast to the low NER capacity, which was observed in experiments using cell-free extracts of TTC lines including 833 K [ 21 ].”
BackgroundMethodResultInfluentialSelf-citationRepair of an Interstrand DNA Cross-link Initiated by ERCC1-XPF Repair/Recombination Nuclease
Kuraoka, I., Kobertz, W. R., Ariza, R. R., Biggerstaff, M., Essigmann, J. M., & Wood, R. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000337200 · Cited by 280 · cited 1×
“In vitro and in vivo data implicate the NER factor ERCC1-XPF in the repair of ICLs in addition to its role in NER [16,17,22].”
BackgroundIncreased nucleotide excision repair in cisplatin-resistant ovarian cancer cells
Ferry, K. V., Hamilton, T. C., & Johnson, S. W. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00441-x · Cited by 275 · cited 1×
“In line with this hypothesis is the finding that acquired resistance towards cisplatin is often correlated with an increased expression of ERCC1 [26,27].”
BackgroundReduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines
Welsh, C., Day, R., McGurk, C., Masters, J. R. W., Wood, R. D., & Köberle, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20134 · Cited by 215 · cited 7×
“As the level of ERCC1-XPF is low in TTC [7] we hypothesized that ERCC1-XPF is the rate-limiting factor responsible for the observed impaired ICL repair in TTC.”
BackgroundMethodInfluentialSelf-citationCuring metastatic cancer: lessons from testicular germ-cell tumours
Masters, J. R. W., & Köberle, B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1120 · Cited by 208 · cited 1×
“Using testis tumour cell lines as a model system may help to define the molecular basis for this hypersensitivity [4].”
BackgroundSelf-citationKaina, B., Margison, G. P., & Christmann, M. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0491-7 · Cited by 174 · cited 1×
“For a number of repair inhibitors clinical studies are now under way [ 33-35 ].”
BackgroundSelf-citationLi, Q., Yu, J., Mu, C., Yunmbam, M. K., Slavsky, D., Cross, C. L., Bostick-Bruton, F., & Reed, E. (2000) · PubMed · Cited by 161
DNA Repair capacity and cisplatin sensitivity of human testis tumour cells
Köberle, B., Grimaldi, K. A., Sunters, A., Hartley, J. A., Kèlland, L. R., & Masters, J. R. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970304)70:5<551::aid-ijc10>3.0.co;2-g · Cited by 152 · cited 6×
“The findings reported here also contrast with earlier studies where it was shown that TTC remove DNA platination damage more slowly from the whole genome and from single genes compared to bladder cancer cells [8].”
BackgroundMethodResultInfluentialSelf-citationXeroderma pigmentosum group A protein loads as a separate factor onto DNA lesions
Rademakers, S., Volker, M., Hoogstraten, D., Nigg, A. L., Moné, M. J., van Zeeland, A. A., Hoeijmakers, J. H. J., Houtsmuller, A. B., & Vermeulen, W. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5755-5767.2003 · Cited by 149 · cited 1×
“It has been shown that the transient participation time of XPA in a single NER event is 4 to 6 min [24], a similar dynamic behaviour was demonstrated for ERCC1-XPF [25].”
BackgroundClingen, P. H., Wu, J., Miller, J. L., MISTRY, N., Chin, F., Wynne, P., Prise, K. M., & Hartley, J. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.03.025 · Cited by 148 · cited 3×
“Similar data were obtained for cisplatin in ERCC1 mutated UV96 hamster cells [12].”
BackgroundResultInfluentialSilva, I. U. D., McHugh, P. J., Clingen, P. H., & Hartley, J. A. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf479 · Cited by 137 · cited 6×
“In addition, in the experimental set-up used earlier platination levels were measured directly after cisplatin treatment and compared to the level 24 h later, while here we compared the level of cisplatininduced intrastrand adducts 6 and 24 h post-treatment because intrastrand adduct formation peaks at 6 h posttreatme…”
BackgroundMethodResultInfluentialEmerging cancer therapeutic opportunities target DNA-repair systems
Ding, J., Miao, Z., Meng, L., & Geng, M. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.04.007 · Cited by 123 · cited 1×
“For a number of repair inhibitors clinical studies are now under way [33-35].”
BackgroundLiedert, B. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl051 · Cited by 115 · cited 2×
“The membrane was blotted in PBS/0,2% Tween-100, 5% non-fat dry milk for 2 h, incubated with an antibody specific for GpG-intrastrand crosslinks [9] at a dilution of 1/500 at 4°C overnight.”
MethodRepair capability and the cellular age response for killing and mutation induction after UV
Wood, R. D., & Burki, H. J. (1982) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(82)90281-0 · Cited by 114 · cited 2×
“As a control we used the ERCC1-deficient cell line 43-3B [11].”
BackgroundMethodDNA repair inhibition: a selective tumour targeting strategy
Madhusudan, S., & Hickson, I. D. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.09.004 · Cited by 112 · cited 1×
“Preclinical studies have confirmed that modulation of repair pathways such as base excision repair, strand break repair, MGMT and PARP can enhance the sensitivity to DNA damaging agents [32].”
BackgroundActivity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair
Gaillard, P.-H. L. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.4.872 · Cited by 107
Targeting DNA repair as a promising approach in cancer therapy
Damia, G. L. M., & D’Incalci, M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.05.003 · Cited by 107 · cited 1×
“For a number of repair inhibitors clinical studies are now under way [33-35].”
BackgroundCheckpoint Signaling from a Single DNA Interstrand Crosslink
Ben-Yehoyada, M., Wang, L. C., Kozekov, I. D., Rizzo, C. J., Gottesman, M. E., & Gautier, J. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.08.014 · Cited by 102 · cited 1×
“However, both Chk1 and Chk2 have been implicated in cisplatin damage signaling [14,15].”
BackgroundXPA protein as a limiting factor for nucleotide excision repair and UV sensitivity in human cells
Köberle, B., Roginskaya, V. Y., & Wood, R. D. (2006) · DNA repair · doi:10.1016/j.dnarep.2005.12.001 · Cited by 92 · cited 17×
“Cisplatininduced intrastrand crosslinks are removed by NER, and our findings suggest that testis tumour cells are basically NER proficient.”
BackgroundInfluentialSelf-citationIn vivo dynamics of chromatin-associated complex formation in mammalian nucleotide excision repair
Moné, M. J., Bernas, T., Dinant, C., Goedvree, F. A., Manders, E. M. M., Volker, M., Houtsmuller, A. B., Hoeijmakers, J. H. J., Vermeulen, W., & van Driel, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403664101 · Cited by 69 · cited 1×
“It has been shown that the transient participation time of XPA in a single NER event is 4 to 6 min [24], a similar dynamic behaviour was demonstrated for ERCC1-XPF [25].”
Background(1999) · PubMed · Cited by 68
Köberle, B., Roginskaya, V. Y., Zima, K. S., Masters, J. R., & Wood, R. D. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20418 · Cited by 35 · cited 15×
“Cisplatininduced intrastrand crosslinks are removed by NER, and our findings suggest that testis tumour cells are basically NER proficient.”
BackgroundInfluentialSelf-citationYagi, T., Matsumura, Y., Sato, M., Nishigori, C., Mori, T., Sijbers, A. M., & Takebe, H. (1998) · Carcinogenesis · doi:10.1093/carcin/19.1.55 · Cited by 24 · cited 1×
“The proteins are unstable and are rapidly degraded without its partner [18].”
Background
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
“and consequently these cell lines are defective in ICL repair and extremely sensitive to cisplatin-induced apoptosis; over-expression of ERCC1/XPF in these cells enhanced ICL repair and reduced the level of apoptosis [81].”
BackgroundSelf-citation
Metadata
- Authors
- Usanova, S., Piée-Staffa, A., Sied, U., Thomale, J., Schneider, A., Kaina, B., & Köberle, B.
- Venue
- Molecular Cancer
- Published
- 2010-09-16
- Volume
- 9
- Issue
- 1
- Pages
- 248-248
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2154925720
- Cited by
- 162
- References
- 38
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.